Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytotoxic cell function in bronchogenic carcinoma.

P Kratikanont, R D deShazo, D E Banks

    Chest
    |July 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Problems+Solutions.

    Postgraduate medicine·2016
    Same author

    Qualitative research: specific designs for qualitative research in emergency care?

    Emergency medicine journal : EMJ·2009
    Same author

    Discourses associated with nursing aged people who are dying in the Australian context: a review of the literature.

    International nursing review·2009
    Same author

    The crusade--a metaphorical explication of the journey made by mature female undergraduate nursing students.

    Rural and remote health·2008
    Same author

    Funding regimes and the implications for delivering quality palliative care nursing within residential aged care units in Australia.

    Rural and remote health·2008
    Same author

    Workplace irritant exposures: do they produce true occupational asthma?

    Current opinion in allergy and clinical immunology·2002

    Peripheral blood lymphocytes in lung cancer patients retain normal cytotoxic function, even when exposed to biologic response modifiers (BRM). These findings suggest that observed defects in lung cytotoxic cells are localized and not systemic in bronchogenic carcinoma.

    Area of Science:

    • Immunology
    • Oncology

    Background:

    • Biologic response modifiers (BRM) like interleukin-2 (IL-2) can enhance lymphocyte cytotoxic activity against tumors.
    • Previous studies indicate defective cytotoxic function in lung and tumor-infiltrating lymphocytes of bronchogenic carcinoma patients.
    • It remains unclear if these defects are intrinsic or a result of the local tumor environment.

    Purpose of the Study:

    • To investigate whether cytotoxic cell function defects in lung cancer patients are primary or secondary to local tumor effects.
    • To determine if peripheral blood lymphocytes from these patients can be effectively stimulated by BRM for enhanced cytotoxic activity.

    Main Methods:

    • Evaluated natural killer (NK) cell and lymphokine-activated killer (LAK) cell activity in mononuclear cells from 11 newly diagnosed bronchogenic carcinoma patients and controls.

    Related Experiment Videos

  • Utilized cultured human squamous cell and adenocarcinoma cell lines to assess LAK activity.
  • Compared NK and LAK activity levels between patients and control groups (non-smokers and smokers).

    • Main Results:

    • Peripheral blood lymphocyte NK and LAK activity in lung cancer patients compared favorably with control groups.
    • Cytotoxic cell function in the peripheral blood of patients remained intact and responsive to BRM stimulation.
    • Observed defects in cytotoxic function appear to be localized to the lung and tumor tissues, not systemic.

    Conclusions:

    • Peripheral blood cytotoxic cell function is preserved in patients with newly diagnosed bronchogenic carcinoma.
    • The responsiveness of these peripheral cells to BRM suggests potential for immunotherapy.
    • Defects in lung cytotoxic cells are likely secondary to local tumor-related factors, not a primary systemic deficit.